MedTrace Logo

Gambro AK200 ULTRA Hemodiafiltration Study

NCT01202708 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-03-11

No results posted yet for this study

Summary

This study is designed to assess the safety, efficacy and dialytic capabilities of hemodiafiltration with on-line prepared substitution fluid using the AK200 ULTRA in comparison to conventional hemodialysis.

Conditions

  • Chronic Renal Failure

Interventions

DEVICE

On line hemofiafiltration

hemodiafiltration with the Gambro AK 200 ULTRA

DEVICE

On line hemodiafiltration

On line hemodiafiltration with the Gambro AK 200 ULTRA System

Sponsors & Collaborators

  • Gambro Renal Products, Inc.

    collaborator INDUSTRY

  • Baxter Healthcare Corporation

    collaborator INDUSTRY

  • Vantive Health LLC

    lead INDUSTRY

Principal Investigators

  • Dr. Susie Q. Lew, MD · George Washington University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-08-31
Primary Completion
2002-04-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01202708 on ClinicalTrials.gov